AR036205A1 - Formas cristalinas de fluvastatina sodio, proceso para su preparacion, y composicion farmaceutica - Google Patents
Formas cristalinas de fluvastatina sodio, proceso para su preparacion, y composicion farmaceuticaInfo
- Publication number
- AR036205A1 AR036205A1 ARP020102927A ARP020102927A AR036205A1 AR 036205 A1 AR036205 A1 AR 036205A1 AR P020102927 A ARP020102927 A AR P020102927A AR P020102927 A ARP020102927 A AR P020102927A AR 036205 A1 AR036205 A1 AR 036205A1
- Authority
- AR
- Argentina
- Prior art keywords
- intensity
- methylethyl
- dihydroxy
- indole
- characteristic
- Prior art date
Links
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 229960000868 fluvastatin sodium Drugs 0.000 title 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 abstract 6
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 5
- 239000002253 acid Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229960003765 fluvastatin Drugs 0.000 abstract 2
- 229910052708 sodium Inorganic materials 0.000 abstract 2
- 239000011734 sodium Substances 0.000 abstract 2
- -1 sodium fluvastatin hydrates Chemical class 0.000 abstract 2
- ZDZJOIIBECYKAJ-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-propan-2-ylindole Chemical compound C12=CC=CC=C2N(C(C)C)C=C1C1=CC=C(F)C=C1 ZDZJOIIBECYKAJ-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/04—Sodium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Formas cristalinas de hidratos de Fluvastatina sodio, referida como formas polimórficas C, D, E y F. Un polimorfo cristalino de sal monosódica de ácido (ñ)-7-(3-(4-fluorfenil)-1-(1-metiletil)-1H-indol-2-il)-3,5-dihidroxi-6-heptenoico, que exhibe un patrón de difracción de polvo de rayos X característico, con picos característicos expresados en valores d (L): 23,8 (vs), 11,8(w), 7,8 (vs), 7,6 (vw), 7,4 (vw), 6,4 (vw), 6,1 (vw), 5,90 (w), 5,00 (vw), 4,88 (w), 4,73 (m), 4,56 (w), 4,40 (vw), 4,12 (vw), 4,03 (vw), 3,96 (vw), 3,50 (vw), 3,36 (vw), 2,93 (vw), donde (vs) = intensidad muy fuerte; (m) = intensidad media; (w) = intensidad débil y (vw) = intensidad muy débil. Un polimorfo cristalino de sal monosódica de ácido (ñ)-7-(3-(4-fluorfenil)-1-(1-metiletil)-1H-indol-2-il)-3,5-dihidroxi-6-heptenoico, que exhibe un patrón de difracción de polvo de rayos X característico, con picos característicos expresados en valores d (L): 24,6 (vs), 12,5 (w), 8,3 (vs), 7,4 (vw), 6,2 (m), 4,97 (w), 4,85 (vw), 4,52 (vw), 4,40 (vw), 4,14 (vw), 3,96 (vw), 3,41 (vw), 3,10 (vw), donde (vs) = intensidad muy fuerte; (m) = intensidad media; (w) = intensidad débil y (vw) = intensidad muy débil. Un polimorfo cristalino de sal monosódica de ácido (ñ)-7-(3-(4-fluorofenil)-1-(1-metiletil)-1H-indol-2-il)-3,5-dihidroxi-6-heptenoico, que puede tener una pequena desviación con los picos característicos expresados en valores d (L) en el patrón de difracción de polvo de rayos X en el rango de 24,6-26,2 (vs), 12,5-13,2 (w), 8,3-8,9 (vs) y 6,2-6,7 (m), dependiendo de la humedad relativa que varía desde 35 a 50%, donde (vs) = intensidad muy fuerte; (m) = intensidad media; (w) = intensidad débil. Un polimorfo cristalino de sal monosódica de ácido (ñ)-7-(3-(4-fluorfenil)-1-(1-metiletil)-1H-indol-2-il)-3,5-dihidroxi-6-heptenoico, que exhibe un patrón de difracción de polvo de rayos X característico, con picos característicos expresados en valores d (L): 27,6 (m), 13,9 (vw), 9,2 (m), 8,5 (vw), 8,1 (vw), 7,4 (vw), 6,9 (s), 6,1 (vw), 4,98 (m), 4,77 (m), 4,63 (m), 4,15 (w), 4,03 (w), 3,97 (vw), 3,52 (vw), 3,33 (vw), 3,08 (vw), 2,99 (vw), donde (s) = intensidad fuerte; (m) = intensidad media; (w) = intensidad débil y (vw) = intensidad muy débil. Un polimorfo cristalino de sal monosódica de ácido (ñ)-7-(3-(4-fluorofenil)-1-(1-metiletil)-1H-indol-2-il)-3,5-dihidroxi-6-heptenoico, que exhibe un patrón de difracción de polvo de rayos X característico, con picos característicos expresados en valores d (L): 29,6 (w), 14,8 (vw), 9,9 (w), 8,6 (vw), 8,3 (vw), 7,4 (s), 6,6 (vw), 6,2 (vw), 5,93 (w), 5,03 (m), 4,94 (m), 4,35 (vw), 4,23 (w), 3,98 (vw), 3,54 (vw), 2,98 (vw), donde (s) = intensidad fuerte; (m) = intensidad media; (w) = intensidad débil y (vw) = intensidad muy débil. Un proceso para la preparación de Fluvastatina sodio Forma A altamente cristalina, que comprende tratar una solución acuosa de sal monosódica de ácido (ñ)-7-(3-(4-fluorfenil)-1-(1-metiletil)-1H-indol-2-il)-3,5-dihidroxi-6-heptenoico, para efectuar por lo menos la precipitación mínima del compuesto, seguido de secado por congelamiento de la suspensión o del compuesto precipitado. Composiciones farmacéuticas que comprenden estas formas cristalinas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01810756 | 2001-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036205A1 true AR036205A1 (es) | 2004-08-18 |
Family
ID=8184071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102927A AR036205A1 (es) | 2001-08-03 | 2002-08-01 | Formas cristalinas de fluvastatina sodio, proceso para su preparacion, y composicion farmaceutica |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6696479B2 (es) |
| EP (1) | EP1429757B8 (es) |
| JP (2) | JP4681808B2 (es) |
| KR (1) | KR100975782B1 (es) |
| CN (2) | CN1536999B (es) |
| AR (1) | AR036205A1 (es) |
| AT (1) | ATE391502T1 (es) |
| AU (1) | AU2002333271B2 (es) |
| CA (1) | CA2454072A1 (es) |
| DE (1) | DE60226044T2 (es) |
| ES (1) | ES2304140T3 (es) |
| HU (1) | HUP0401141A3 (es) |
| IL (2) | IL159861A0 (es) |
| PL (1) | PL366905A1 (es) |
| RU (1) | RU2334738C2 (es) |
| WO (1) | WO2003013512A2 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087631B2 (en) * | 2002-07-18 | 2006-08-08 | Inotek Pharmaceuticals Corporation | Aryltetrazole compounds, and compositions thereof |
| AU2003250086A1 (en) * | 2002-07-26 | 2004-02-23 | Ciba Specialty Chemicals Holging Inc. | Crystalline polymorphic and amorphous forms of benazepril hydrochloride |
| WO2004096765A2 (en) * | 2003-05-01 | 2004-11-11 | Morepen Laboratories Ltd. | A novel crystalline polymorph of fluvastatin sodium and a process for preparing it |
| KR20070094805A (ko) | 2003-06-18 | 2007-09-21 | 테바 파마슈티컬 인더스트리즈 리미티드 | 플루바스타틴 나트륨 결정형 ｘｉｖ, ｌｘｘｉｉｉ,ｌｘｘｉｘ, ｌｘｘｘ 및 ｌｘｘｘｖｉｉ, 이의 제조 방법,이를 포함하는 조성물 및 이를 사용하는 방법 |
| US7368581B2 (en) | 2003-06-18 | 2008-05-06 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of fluvastatin sodium crystal from XIV |
| US7368468B2 (en) | 2003-06-18 | 2008-05-06 | Teva Pharmaceutical Industries Ltd. | Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them |
| WO2005037424A1 (en) * | 2003-10-06 | 2005-04-28 | Solvias Ag | Process for the parallel detection of crystalline forms of molecular solids |
| US7432380B2 (en) | 2003-10-16 | 2008-10-07 | Ciba Specialty Chemicals Corp. | Crystalline form of Fluvastatin sodium |
| US7851624B2 (en) * | 2003-12-24 | 2010-12-14 | Teva Pharamaceutical Industries Ltd. | Triol form of rosuvastatin and synthesis of rosuvastatin |
| US20070179166A1 (en) * | 2003-12-24 | 2007-08-02 | Valerie Niddam-Hildesheim | Process for preparation of statins with high syn to anti ratio |
| WO2005080332A1 (en) * | 2004-01-14 | 2005-09-01 | Cadila Healthcare Limited | Novel form of fluvastatin sodium |
| US20070173536A1 (en) * | 2004-02-06 | 2007-07-26 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of zolmitriptan |
| US7241800B2 (en) | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
| WO2006021967A1 (en) * | 2004-08-26 | 2006-03-02 | Biocon Limited | Process for the preparation of fluvastatin sodium form a. |
| WO2006030304A2 (en) * | 2004-09-17 | 2006-03-23 | Ranbaxy Laboratories Limited | Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof |
| US7795451B2 (en) * | 2005-02-11 | 2010-09-14 | Jubilant Organosys Limited | Polymorphic forms of fluvastatin sodium and process for preparing the same |
| WO2006109147A1 (en) * | 2005-04-12 | 2006-10-19 | Glenmark Pharmaceuticals Limited | Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same |
| WO2007039784A2 (en) * | 2005-10-06 | 2007-04-12 | Wockhardt Limited | A novel crystalline polymorph of fluvastatin sodium and process for preparing it |
| US20090082572A1 (en) * | 2005-11-14 | 2009-03-26 | Hetero Drugs Limited | Process for amorphous esomeprazole |
| JP2007246522A (ja) * | 2006-02-27 | 2007-09-27 | Teva Pharmaceutical Industries Ltd | フルバスタチンナトリウムの新規形及びその調製方法 |
| US20110015247A1 (en) * | 2008-04-04 | 2011-01-20 | Shodhana Laboratories Limited | Novel crystalline form of carvedilol dihydrogen phosphate and related processes |
| CN101684121B (zh) * | 2008-09-22 | 2013-04-03 | 重庆医药工业研究院有限责任公司 | 培美曲塞二酸的新晶型及其制备方法 |
| JP6115288B2 (ja) * | 2012-04-27 | 2017-04-19 | 株式会社島津製作所 | 質量分析におけるピーク検出方法及びそのシステム |
| TW201806928A (zh) * | 2016-07-01 | 2018-03-01 | 第一三共股份有限公司 | 胺基羧酸之酸加成鹽的結晶及其製造方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984002131A1 (fr) * | 1982-11-22 | 1984-06-07 | Sandoz Ag | Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques |
| US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
| PH23486A (en) * | 1982-11-22 | 1989-08-16 | Sanzoz Inc | Indole analogs of mevalonolactone,pharmaceutical compositions containing the same and method of use thereof |
| HU217629B (hu) * | 1991-12-12 | 2000-03-28 | Novartis Ag. | Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására |
| HRP960313B1 (en) | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| WO1997049681A1 (en) * | 1996-06-24 | 1997-12-31 | Astra Aktiebolag (Publ) | Polymorphic compounds |
| DE60112956T2 (de) * | 2000-10-31 | 2006-06-14 | Ciba Sc Holding Ag | Kristalline formen von fluvastatin sodium |
-
2002
- 2002-07-25 DE DE60226044T patent/DE60226044T2/de not_active Expired - Lifetime
- 2002-07-25 CN CN028151321A patent/CN1536999B/zh not_active Expired - Fee Related
- 2002-07-25 IL IL15986102A patent/IL159861A0/xx active IP Right Grant
- 2002-07-25 KR KR1020047001615A patent/KR100975782B1/ko not_active Expired - Fee Related
- 2002-07-25 CN CN2011103995817A patent/CN102516150A/zh active Pending
- 2002-07-25 JP JP2003518521A patent/JP4681808B2/ja not_active Expired - Fee Related
- 2002-07-25 RU RU2004106528/04A patent/RU2334738C2/ru not_active IP Right Cessation
- 2002-07-25 CA CA002454072A patent/CA2454072A1/en not_active Abandoned
- 2002-07-25 PL PL02366905A patent/PL366905A1/xx not_active Application Discontinuation
- 2002-07-25 AU AU2002333271A patent/AU2002333271B2/en not_active Ceased
- 2002-07-25 AT AT02794517T patent/ATE391502T1/de not_active IP Right Cessation
- 2002-07-25 HU HU0401141A patent/HUP0401141A3/hu unknown
- 2002-07-25 WO PCT/EP2002/008276 patent/WO2003013512A2/en not_active Ceased
- 2002-07-25 ES ES02794517T patent/ES2304140T3/es not_active Expired - Lifetime
- 2002-07-25 EP EP02794517A patent/EP1429757B8/en not_active Expired - Lifetime
- 2002-07-30 US US10/208,687 patent/US6696479B2/en not_active Expired - Lifetime
- 2002-08-01 AR ARP020102927A patent/AR036205A1/es unknown
-
2004
- 2004-01-14 IL IL159861A patent/IL159861A/en not_active IP Right Cessation
-
2010
- 2010-07-23 JP JP2010165635A patent/JP2010265308A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1429757B1 (en) | 2008-04-09 |
| CA2454072A1 (en) | 2003-02-20 |
| EP1429757B8 (en) | 2008-07-16 |
| KR20040022226A (ko) | 2004-03-11 |
| JP2005501838A (ja) | 2005-01-20 |
| WO2003013512A2 (en) | 2003-02-20 |
| AU2002333271B2 (en) | 2007-08-09 |
| JP4681808B2 (ja) | 2011-05-11 |
| HUP0401141A2 (hu) | 2004-09-28 |
| JP2010265308A (ja) | 2010-11-25 |
| KR100975782B1 (ko) | 2010-08-17 |
| DE60226044D1 (de) | 2008-05-21 |
| CN1536999B (zh) | 2012-08-08 |
| WO2003013512A3 (en) | 2003-11-20 |
| IL159861A (en) | 2009-02-11 |
| RU2334738C2 (ru) | 2008-09-27 |
| CN1536999A (zh) | 2004-10-13 |
| US6696479B2 (en) | 2004-02-24 |
| ES2304140T3 (es) | 2008-09-16 |
| RU2004106528A (ru) | 2005-07-27 |
| IL159861A0 (en) | 2004-06-20 |
| DE60226044T2 (de) | 2009-05-14 |
| CN102516150A (zh) | 2012-06-27 |
| EP1429757A2 (en) | 2004-06-23 |
| ATE391502T1 (de) | 2008-04-15 |
| PL366905A1 (en) | 2005-02-07 |
| HUP0401141A3 (en) | 2011-07-28 |
| US20030032666A1 (en) | 2003-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU92004564A (ru) | Фармацевтические композиции и способ их получения | |
| CA2085037A1 (en) | Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor compound | |
| JP2005501838A5 (es) | ||
| AR022600A1 (es) | ACETATO DE TER-BUTIL (E) (6-{2-[4-(4-FLUOROFENIL)-6-ISOPROPIL-2-METIL (METILSULFONIL) AMINO] PIRIMIDIN-5-IL VINIL} (4R, 6S) -2,2-DIMETIL [1,3] DIOXAN -4- ILO), PROCESO PARA SU FABRICACIoN ,COMPUESTOS INVOLUCRADOS EN DICHO PROCESO Y PROCESO PARA LA FABRICACION DE UN COMPUESTO INHIBIDOR DE LA HMG COA | |
| CO5640116A2 (es) | Produccion mejorada de sal de calcio de rosuvastatina | |
| WO2006061638A3 (en) | Heterocycle derivatives as histone deacetylase (hdac) inhibitors | |
| BR0108893B1 (pt) | composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos. | |
| CY1109104T1 (el) | 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου | |
| WO2004020431A3 (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| IL190346A0 (en) | Pharmaceutical preparation having excellent photostability | |
| JP2007016035A5 (es) | ||
| ATE294185T1 (de) | Neue pyrazin-derivate oder salze davon, pharmazeutische zusammensetzungen, die die derivate oder deren salze enthalten und intermediäre zur herstellung der derivate | |
| WO2007072158A3 (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| ATE165830T1 (de) | Dihydro pyrazolopyrrole | |
| WO2004098494A3 (en) | Compounds, compositions, and methods | |
| EA200400476A1 (ru) | Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция | |
| WO2003053368A3 (en) | Chalcone derivatives and their use to treat diseases | |
| PT1078923E (pt) | Processo para a preparacao de derivados de benzotiofeno | |
| EP1429757B8 (en) | Crystalline forms of fluvastatin sodium | |
| CY1105387T1 (el) | Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου | |
| EA200201149A1 (ru) | Фармацевтические композиции и способы для предотвращения рецидива мигрени | |
| NZ540972A (en) | Novel 2,4-diamino-1,3,5-triazine derivative | |
| ATE266029T1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung | |
| BR0207102A (pt) | Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença | |
| WO2002072581A3 (en) | Pyrazolopyriadine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |